Synchronous Presentation of Two Extranodal Lymphomas: Follicular Lymphoma and Extranodal Marginal Zone




Extranodal marginal zone lymphomas of mucosa-associated 
lymphoid tissue (MALTomas) originate from mucosa-associated 
lymphoid tissue (MALT) and present as low-grade, localized 
lymphomas, forming 8% of all non-Hodgkin lymphomas (NHLs). 
The most common localization for MALTomas is the stomach [1]. 
Follicular lymphoma (FL), the second most common NHL type in 
Western countries, is another low-grade lymphoma originating from 
germinal center B cells [2]. FL generally presents with extensive 
lymphadenopathy, bone marrow involvement, splenomegaly, and less 
commonly as extranodal disease.
Herein, we report a case of synchronous MALToma and FL in 
a patient’s two different extranodal tissues.
Clinical history
A 78-year-old male patient applied to our hospital with dyspeptic 
symptoms. All the laboratory tests were in normal ranges, no 
palpable lymph node was found on physical examination, and 
a gastroduodenoscopy was performed. The laboratory results were 
normal, in addition to the lactate dehydrogenase (LDH) level of 
206 U/L and b2-microglobulin level of 2.3 mg/L. The endoscopic 
biopsy revealed a slightly diffuse, submucosal  lymphoid  infiltration 
of small lymphocytes with no evident lymphoepithelial lesions. The 
infiltration had no nodular or follicular-like pattern. The neoplastic cells 
immunostained  positively  for  only  cluster  of  differentiation (CD)20, 
CD43,  and  B-cell  lymphoma  (bcl)-2.  Other  low-grade  lymphoma 
markers used in differential diagnosis (bcl-6, cyclin D1, CD10, CD5, 
and CD23) were all negative, with a Ki67 proliferation rate of 3%-5%. 
The diagnosis was given as MALT lymphoma. After the diagnosis, 
a bone marrow biopsy was performed; the bone marrow was not 
infiltrated, showing normal cellularity.
After the diagnosis, a positron emission tomography/computed 
tomography (PET/CT) was performed, and this technique revealed 
a parenchymal lesion in the posterobasal segment of the right lung in 
the paravertebral region. In addition to this finding, slightly increased 
18-fluorodeoxyglucose (FDG) involvement was found in millimetric 
nodular opacities seen in the left apex, the left upper lingular segment 
of the left lung, and the middle lobe medial segment of the right lung. 
Moreover, an increased 18-FDG involvement was revealed in the left 
palatine tonsil, intraaortacaval region of the abdomen, and multiple 
bone regions. Depending on this extensive disease, lung cancer was 
thought to be a secondary focus, and a wedge biopsy of the lung 
lesion was performed.
During microscopic evaluation of the lung, a small lymphocytic 
infiltration  predominantly  with  nodular  and  follicular  pattern  was 
observed.  The  infiltration  was  thought  to  be  the  MALT  lymphoma 
with nodular pattern; however,  the neoplastic cells showed diffuse 
immunoexpression of bcl-2, bcl-6, CD20, and CD10. The diagnosis of 
the lung biopsy was given as FL grade 3A with numerous centroblasts 
and the characteristic targetoid pattern of Ki67 with a rate of 25%. 
Upon obtaining these results, the previous endoscopic gastric biopsy 
was reexamined, but the diagnosis was the same.
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Synchronous malignancies are rare conditions in oncology practices, generally seen as solid tumors with hematological neoplasms. 
However, occurrence of two different hematological malignancies in the same patient is extremely rare. Two primary malignancies should 
be considered especially in patients with extraordinary presentations and treatment resistance.
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Just before the diagnosis of the second lymphoma and after the 
wedge biopsy, the patient was given two cycles of cyclophosphamide, 
doxorubicin,  vincristine,  and  prednisone  (CHOP)  because  of  the 
progressive clinical symptoms, in addition to antibiotherapy for 
Helicobacter pylori. After the diagnosis of FL, the Follicular Lymphoma 
International Prognostic Index (FLIPI) prognostic index score was 
calculated as “3: high risk”, and rituximab was added to the treatment 
protocol. After  four  cycles  of  CHOP plus  the monoclonal  antibody 
rituximab  (R-CHOP),  the patient achieved complete  response with 
no pathological 18-FDG involvement on PET/CT and continued with 
rituximab maintenance therapy. The patient was disease free after 
1-year follow-up with complete response.
Discussion
The frequency of occurrence of synchronous multiple malignancies 
is very low among the population. After the treatment of primary 
solid tumors, hematological secondary malignancies due to chemo/ 
radiotherapy can be seen [3]. The most commonly reported double 
malignancies are solid tumors with hematological neoplasms, such 
as gastric cancer with diffuse large B-cell lymphoma (DLBCL), lung 
adenocarcinoma with chronic myeloid leukemia, colon cancer with 
myeloma, and lung cancer with myeloma [3]. However, synchronous 
presentation of two hematologic neoplasms is extremely rare and 
reported generally as myeloproliferative diseases (MPDs) with 
lymphoproliferative diseases [3], and the combinations were as 
follows: concomitant histiocytic sarcoma  and  DLBCL  [4],  DLBCL 
with myeloma [5], mantle cell  lymphoma with chronic  lymphocytic 
leukemia  (CLL)  [6, 7],  and DLBCL with Hodgkin’s  lymphoma  [8, 9], 
MPDs with CLL, and MPDs with hairy cell leukemia [10].
MALToma originates from the MALT tissue, which is widely localized 
throughout the whole body, such as in the gastrointestinal tract, salivary 
glands, lungs, and so on. The most common organ of localization 
is  the  stomach, with  an  incidence  of  50% of  the  gastrointestinal 
MALTomas [11]. The diagnosis generally depends on the exclusion 
of other types of low-grade lymphomas with the presence of 
Fig. 1 A. Small lymphocytic infiltration located in the submu- 
cosal region by gastric endoscopic biopsy (hematoxylin and 
eosin, ×100)
 Fig. 1 B. CD20 positivity (diaminobenzidine, ×100)
Fig. 1 C. BCL2 positivity (diaminobenzidine, ×100) Fig. 1 D. BCL6 negativity (diaminobenzidine, ×100)
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characteristic lymphoepithelial lesions (replacement of the epithelial 
cells with lymphoid cells) [12]. The immunohistochemical features are 
the same as normal MALT tissue, showing CD20 positivity, as well as 
CD5, CD10, and cyclin D1 negativity (1). The disease is commonly 
found to be associated with Helicobacter pylori, and the treatment 
should also include antibiotherapy for this microorganism.
FL is a lymphoma originating from the germinal center B 
cells with a bcl2 rearrangement and t(14;18) translocation. The 
grading depends on the number of centroblasts, and the growth 
pattern  (nodular/diffuse) should  be  stated  in  the  pathology  report 
(2). The characteristic histological appearance includes a high 
number of neoplastic follicles with no mantle zones or tingible 
body macrophages in a back-to-back arrangement showing CD20, 
CD10, bcl2, and bcl6 positivity and CD5 negativity. The prognosis 
correlates with the grade and the extent of the disease.
Extranodal FL, although rare, may occur in any area such as the 
skin, gastrointestinal tract, breast, and testis. Primary pulmonary 
lymphoma is one of the rare ones, comprising only 4% of all 
extranodal NHLs [11, 13].
Multiple lymphomas may rarely occur simultaneously and cause 
diagnostic problems  in hematology practice. The firstly diagnosed 




with gastric MALToma in the literature to our knowledge. As in our 
case, symptoms may overlap, causing delay in identification of the 
synchronous neoplasm. But an atypical presentation should remind 
of a synchronous neoplasm, and the treatment needs to be planned 
including both diseases.
Fig. 2 A. Nodular/follicular pattern of small lymphocytic infiltration 
in the lung wedge resection (hematoxylin and eosin, ×40)
Fig. 2 B. CD20 positivity (diaminobenzidine, ×200)
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